Former CEO who oversaw $3.9B sale of Idenix to head new Cambridge biotech
December 01, 2014 at 08:00 AM EST
The CEO who sold Idenix Pharmaceuticals to Merck & Co. in August for $3.9 billion, the area's largest biotech acquisition this year, has a new job...
